5 Reasons Big Biotech Could Gain 25%-30%

Leerink analyst Geoff Porges sees 25% or better upside ahead for Big Biotech. Here's why.....»»

Category: blogSource: barronsMay 19th, 2017

Market Snapshot: Stocks slide after 6-day rally; inflation remains in focus

U.S. stocks trade mostly lower on Tuesday, with investors finding few reasons to keep pushing shares higher following a six-day rally that gave indexes their biggest one-week percentage gain in years......»»

Category: topSource: marketwatchFeb 20th, 2018

Why Theravance Biopharma Shares Are Soaring

Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech......»»

Category: blogSource: 247wallstFeb 7th, 2018

Biotech Ready to Bust Out

On Monday, the Nasdaq Biotech Index jumped 3.1%, its biggest gain in six months, taking it to a new 52-week high......»»

Category: topSource: barronsJan 27th, 2018

4 Reasons Exelixis, Inc. More Than Doubled in 2017

A 104% gain last year wouldn't have been possible without lead drug Cabometyx......»»

Category: topSource: foxnewsJan 10th, 2018

Tesla posted a big gain on Monday — here are 3 reasons why that happened (TSLA)

Reuters / Rebecca Cook Tesla shares spiked 6% on Monday, seemingly for no reason. .....»»

Category: topSource: businessinsiderJan 9th, 2018

Here"s Why Intellia Therapeutics Inc. Fell 14.7% in December

Another CRISPR-based biotech's gain was Intellia's loss last month......»»

Category: topSource: foxnewsJan 4th, 2018

18 Reasons I Like Biotech Stocks in 2018

Investing in bio.....»»

Category: futuresSource: nasdaqJan 4th, 2018

Netflix shares gain premarket after upgrade at Macquarie Research

Shares of Netflix Inc. were upgraded to outperform from a neutral rating by analysts at Macquarie Research on Tuesday. The main reasons for .....»»

Category: topSource: marketwatchJan 2nd, 2018

Market Snapshot: Dow, S&P 500 post fifth straight weekly gain ahead of Christmas holiday

U.S. stocks ended slightly lower on Friday, as investors found few reasons to keep pushing shares higher going into a holiday-shortened week, especially with major indexes near records and posting their fifth straight weekly advance......»»

Category: topSource: marketwatchDec 22nd, 2017

5 Reasons Why 2018 Could be Good for IPO ETFs

IPO ETFs can gain further momentum in 2018. Here is why. After a subdued 2016, the U.S. IPO market catapulted in 2017. The rise was credited to a surging stock market, improving economic fundamentals and increasing co.....»»

Category: personnelSource: nytDec 21st, 2017

8 Reasons Why Entrepreneurs Are Happy Net Neutrality Is Being Dismantled

Net Neutrality is not just a consumer issue. Entrepreneurs and small businesses stand to gain a lot from its dismantling......»»

Category: topSource: incDec 18th, 2017

Value Biotech ETFs to Buy Now

A few reasons why you should buy value biotech ETFs for 2018 The biotech sector has had a great year, with SPDR S&P Biotech ETF XBI adding over 39% (as of Dec 11, 2017). Ebbing tensions over the price gouging issue, hopes o.....»»

Category: dealsSource: nytDec 13th, 2017

Riot Blockchain"s "Coinsquare" Gets Vote Of Confidence With New Investment

Riot Blockchain Inc (NASDAQ: RIOT), a former biotech company that aims to gain exposure to the blockchain ecosystem with a focus on bitcoin and Ethereum, announced a new investment Monday.  read more.....»»

Category: blogSource: benzingaDec 4th, 2017

3 Reasons Pfizer Should Buy Celgene in 2018

A marriage between this big pharma and big biotech could make both companies' shareholders happy......»»

Category: topSource: foxnewsDec 4th, 2017

4 Reasons Why You Should Invest in CF Industries Stock Now

CF Industries (CF) is well positioned to gain from .....»»

Category: personnelSource: nytNov 30th, 2017

3 Reasons Novavax Stock Could Double in 2018

This biotech's future could be much brighter than its past......»»

Category: topSource: foxnewsNov 18th, 2017

3 Reasons Behind Exelixis Stock"s Big Bounce

A great performance in Q3 fueled optimism about the biotech's future......»»

Category: topSource: foxnewsNov 3rd, 2017

Myriad Reasons to Short

I’ve shorted Myriad Genetics (MYGN) with a stop at 35.84. Biotech companies make me a bit jumpy, of course, so the position is pretty small. Here’s recent activity:.....»»

Category: blogSource: slopeofhopeOct 24th, 2017

3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead. After a lackluster performanc.....»»

Category: dealsSource: nytSep 13th, 2017

U.S. stocks end higher; Nasdaq boosted by biotech gain

U.S. stocks ended higher on Wednesday, with the Nasdaq seeing a particular gain on the strength of biotechnology companies, while the S&P 500 closed higher for a fourth straight session. The Dow Jones Industrial A.....»»

Category: topSource: marketwatchAug 30th, 2017